French Medtech Firm RDS Secures €14m for Global Expansion
French medical tech firm RDS has secured €14m in a Series A funding round, led by SPI Fund and Critical Path Ventures. The company aims to expand its sales team, scale production, and launch clinical trials in Europe and the US with the fresh capital.
RDS, founded in 2020, has raised a total of €28m in capital and non-dilutive financing. The latest round saw participation from previous investors MACSF and Capital Grand Est, along with new backer Critical Path Ventures.
The company's MultiSense solution enables remote monitoring of six vital signs, currently used in 15 hospitals across France, Belgium, and Germany. Professor Jacques Marescaux, a scientific board member, lauds the patch's medical and economic benefits. With the global vital signs monitoring market projected to reach $15bn by 2023 and grow at 15% annually, RDS plans to capitalize on this opportunity.
Backed by the French state through Bpifrance's SPI Fund, RDS is poised to scale and commercialize its cloud-linked device. The company's successful funding round reflects investor confidence in its innovative remote patient monitoring technology.
